Finance

Lists
207940:KRX
Samsung Biologics Co Ltd
₩1,447,000.00
-2.03%
(-30,000.00) 1D
Sep 4, 3:30:09 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 207940...
Open
₩1,484,000
High
₩1,487,000
Low
₩1,433,000
Mkt. cap
66.98T
Avg. vol.
63.23K
Volume
45.40K
P/E ratio
31.28
52-wk high
₩1,987,000
52-wk low
₩982,000
EPS
₩46,253
Shares outstanding
46.29M
No. of employees
5K
Open
₩1,484,000
High
₩1,487,000
Low
₩1,433,000
Mkt. cap
66.98T
Avg. vol.
63.23K
Volume
45.40K
P/E ratio
31.28
52-wk high
₩1,987,000
52-wk low
₩982,000
EPS
₩46,253
Shares outstanding
46.29M
No. of employees
5K
News stories
From web sources and news partners
Profile
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines. The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
About Samsung Biologics Co Ltd
CEOJohn Rim
Employees5.33K
Founded2011
Headquarters-
SectorHealth care
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.66T
1.29T
1.26T
1.32T
Cost of goods sold
685.41B
614.00B
578.27B
622.58B
Cost of revenue
685.41B
614.00B
578.27B
622.58B
Research and development expenses
34.28B
-
7.24B
9.03B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
198.01B
144.00B
81.68B
87.90B
Operating expense
245.96B
144.00B
98.09B
111.89B
Total operating expenses
931.37B
758.00B
676.37B
734.47B
Operating income
728.85B
528.00B
580.75B
586.44B
Other non operating income
4.54B
47.00B
2.44B
8.00B
EBT including unusual items
767.00B
575.00B
640.59B
584.63B
EBT excluding unusual items
767.42B
575.00B
640.59B
585.31B
Income tax expense
192.54B
122.00B
171.35B
153.97B
Effective tax rate
25.10%
21.22%
26.75%
26.34%
Other operating expenses
597.95M
-
578.26M
5.68B
Net income
574.46B
510.00B
469.25B
430.65B
Net profit margin
34.60%
39.66%
37.33%
32.60%
Earnings per share
8.07K
8.72K
10.15K
9.31K
Interest and investment income
13.35B
-
13.97B
13.29B
Interest expense
-10.71B
-
-7.15B
-8.78B
Net interest expenses
2.64B
-
6.83B
4.51B
Depreciation and amortization charges
8.84B
-
5.07B
5.26B
EBITDA
907.77B
-
675.31B
698.52B
Gain or loss from assets sale
412.61M
-
18.00K
676.54M
AI content may include mistakes. Learn more
Google apps